Drugs for Treating Systemic Lupus Erythematosus: Global Markets

Report Code: PHM159A

Publish Date: Mar 2014

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for drugs to treat systemic lupus erythematosus (SLE) is expected to reach $950.2 million in 2013 and $2.6 billion in 2018, a compound annual growth rate (CAGR) of 22.4%.

Report Includes

  • An overview of the global market for drugs and therapeutics used to treat systemic lupus erythematosus (SLE) 
  • Analyses of global market trends, with data from 2013 and projections of CAGRs through 2018.
  • Analyses of factors influencing market demand such as the industry's structure, governmental regulations, and developing technologies
  • Details concerning the developmental product pipeline for therapeutics uesd to treat SLE
  • Profiles of leading companies in the industry.

SCOPE OF REPORT

The scope of this report focuses on the pharmaceutical segment. We have compiled a study of the market, as well as current and emerging modes of treatment. We present the market segment’s economic environment, market factors and potential, and forecasts for 2013 to 2018. This study will be of interest to the drug industry, patients and the medical community. It will also be of interest to suppliers of products and services to this market area.

ANALYST’S CREDENTIALS

Dr. Sanjukta Bhattacharyya is the BCC Research analyst of this report. She holds a PhD in endocrinology from the University of Calcutta in India, and has more than 14 years of experience in the pharmaceutical industry, having been associated with leading pharmaceutical companies in clinical research and project management. Of note was the successful clinical development of an antimalarial new chemical entity (NCE) (Synriam), leading to its regulatory submission and transitioning to market. Synriam became the first new drug by an Indian pharmaceutical company. Sanjukta has played significant roles in various licensing deals and alliance management for NCE codevelopment between partners. Skilled in ICH/GCP guidelines and protocols, and experienced in conducting clinical trials, Sanjukta also does medical writing involving the preparation of clinical study protocols, various relevant documents, and study reports. She also has several publications in peer-reviewed journals.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Drugs for Treating Systemic Lupus Erythematosus: Global Markets129Free
Chapter- 1: INTRODUCTION2Free
Chapter- 2: EXECUTIVE SUMMARY8Free
Chapter- 3: OVERVIEW16Free
Chapter- 4: CURRENT MEDICAL PRACTICE AND MARKET PROFILES16Free
Chapter- 5: CURRENT THERAPIES 13Free
Chapter- 6: UNMET NEEDS5Free
Chapter- 7: EMERGING THERAPIES10Free
Chapter- 8: MARKET OUTLOOK18Free
Chapter- 9: PATENTS17Free
Chapter- 10: C. CRAMER & CO. GMBH24Free

Related Reports

Immunoassays: Technologies and Global Markets

Published - Apr 2013 | Publisher - Carlet Auguste | Code - BIO033B

The global demand for immunoassay testing was nearly $15.6 billion in 2011 and $16.3 billion in 2012. This market is expected to grow to $20.5 billion by 2017, at a compound annual growth rate (CAGR) of 4.7% from 2012 to 2017.

Labeling and Linkage Agents for Immunoassays and Gene Probes

Published - Oct 2011 | Publisher - Jackson Highsmith | Code - BIO038C

The market for immunoagents, probes and molecular diagnostics was $29.6 billion in 2010. This market is projected to be $33.5 billion in 2011 and will increase up to $60.3 billion by 2016 at a compound annual growth rate (CAGR) of 12.5%.

Drugs and Treatments for Autoimmune Diseases: Global Markets

Published - Oct 2011 | Publisher - Peggy Lehr | Code - HLC091A

The global market for autoimmune treatments reached at $34 billion in 2010, it is expected to reach at $38.9 billion by 2011 and it will further grow to $55 billion by 2016 at a compounded annual growth rate (CAGR) of 7.2%.

Recent Reports

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Active Pharmaceutical Ingredients: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM200C

The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.

Global Market for Contract Research Organization (CRO) Services

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM186C

The global market for contract research organization (CRO) services is expected to grow from $111.8 billion in 2024 and is projected to reach $166.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

Global Oncology Pharmaceuticals Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM256B

The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.

Excipients in Pharmaceuticals: Global Markets to 2029

Published - Sep 2024 | Publisher - Gundreddy Gopinadh | Code - PHM010M

The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.

Top Trending Reports

AI in Clinical and Molecular Diagnostics Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - BIO261A

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Medical Devices: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC170F

The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

CRISPR Technology: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Drugs for Treating Systemic Lupus Erythematosus: Global Markets
Customize Report